Kiniksa Pharmaceuticals Ltd (KNSA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $7.57B
Last updated: Nov 17, 2026 at 11:06 AM ET
Kiniksa Pharmaceuticals Ltd (KNSA) Earnings: Report Dates and Results
Kiniksa Pharmaceuticals (KNSA) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Kiniksa Pharmaceuticals reported EPS of $0.56, above the $0.32 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
KNSA has an expected report date of Feb 22, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 70.6% above the $0.17 reported for the quarter ended Dec 31, 2025.
KNSA Earnings Call
The latest KNSA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 34 quarters below that had an estimate, KNSA beat 17, missed 16 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $285.97M, up 58.1% from $180.85M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.56 | $0.32 | $0.27 - $0.37 | +75.00% | Beat | +143.5% | 4 | 2 up, 2 down | Oct 27, 2026 | $285.97M |
| Jun 30, 2026 | $0.30 | $0.30 | $0.27 - $0.30 | 0.00% | In line | +30.4% | 4 | 0 up, 0 down | Jul 28, 2026 | $243.60M |
| Mar 31, 2026 | $0.27 | $0.16 | $0.13 - $0.20 | +68.75% | Beat | +145.5% | 3 | 0 up, 1 down | Apr 28, 2026 | $214.27M |
| Dec 31, 2025 | $0.17 | $0.40 | $0.29 - $0.53 | -57.50% | Miss | N/A | 5 | 0 up, 0 down | Feb 24, 2026 | $202.13M |
| Sep 30, 2025 | $0.23 | $0.37 | $0.26 - $0.57 | -37.84% | Miss | N/A | 5 | 1 up, 1 down | Oct 28, 2025 | $180.85M |
| Jun 30, 2025 | $0.23 | $0.26 | $0.16 - $0.37 | -11.54% | Miss | N/A | 5 | 0 up, 1 down | Jul 29, 2025 | $156.80M |
| Mar 31, 2025 | $0.11 | $0.28 | -$0.14 - $0.71 | -60.71% | Miss | N/A | 4 | 0 up, 0 down | Apr 29, 2025 | $137.78M |
| Dec 31, 2024 | -$0.12 | $0.02 | -$0.13 - $0.33 | -700.00% | Miss | -134.3% | 3 | 0 up, 0 down | Feb 25, 2025 | $122.54M |
| Sep 30, 2024 | -$0.18 | $0.07 | -$0.06 - $0.18 | -357.14% | Miss | N/A | 5 | 1 up, 0 down | Oct 29, 2024 | $112.21M |
| Jun 30, 2024 | -$0.06 | $0.01 | N/A | -700.00% | Miss | -128.6% | 4 | 0 up, 0 down | Jul 23, 2024 | $108.63M |
| Mar 31, 2024 | -$0.25 | -$0.08 | N/A | -212.50% | Miss | N/A | 3 | 0 up, 0 down | Apr 23, 2024 | $79.86M |
| Dec 31, 2023 | $0.35 | -$0.14 | -$0.23 - -$0.04 | +350.00% | Beat | +483.3% | 4 | 0 up, 0 down | Feb 28, 2024 | $83.39M |
| Sep 30, 2023 | -$0.20 | -$0.16 | -$0.22 - -$0.11 | -25.00% | Miss | -106.3% | 4 | 0 up, 0 down | Oct 31, 2023 | $67.05M |
| Jun 30, 2023 | $0.21 | -$0.13 | -$0.20 - -$0.12 | +261.54% | Beat | N/A | 4 | 0 up, 0 down | Jul 25, 2023 | $71.47M |
| Mar 31, 2023 | -$0.18 | -$0.21 | -$0.28 - -$0.12 | +14.29% | Beat | N/A | 4 | 0 up, 0 down | May 2, 2023 | $48.34M |
| Dec 31, 2022 | $0.06 | -$0.14 | N/A | +142.86% | Beat | N/A | 4 | 0 up, 0 down | Feb 28, 2023 | $61.88M |
| Sep 30, 2022 | $3.18 | $0.83 | -$0.34 - $0.87 | +283.13% | Beat | N/A | 4 | 0 up, 0 down | Nov 1, 2022 | $99.14M |
| Jun 30, 2022 | -$0.29 | -$0.39 | N/A | +25.64% | Beat | N/A | 4 | 0 up, 0 down | Aug 3, 2022 | $26.97M |
| Mar 31, 2022 | -$0.36 | -$0.26 | N/A | -38.46% | Miss | N/A | 3 | 1 up, 0 down | May 3, 2022 | $32.19M |
| Dec 31, 2021 | -$0.53 | -$0.42 | -$0.47 - -$0.33 | -26.19% | Miss | N/A | 4 | N/A | Feb 22, 2022 | $18.75M |
| Sep 30, 2021 | -$0.44 | -$0.63 | -$0.70 - -$0.62 | +30.16% | Beat | N/A | 4 | N/A | Nov 1, 2021 | $12.10M |
| Jun 30, 2021 | -$0.61 | -$0.77 | -$1.16 - -$0.63 | +20.78% | Beat | N/A | 4 | N/A | Aug 3, 2021 | $7.70M |
| Mar 31, 2021 | -$0.72 | -$0.63 | -$0.92 - -$0.35 | -14.29% | Miss | N/A | 4 | N/A | May 4, 2021 | N/A |
| Dec 31, 2020 | -$0.79 | -$0.62 | -$0.70 - -$0.55 | -27.42% | Miss | N/A | 4 | N/A | Feb 23, 2021 | N/A |
| Sep 30, 2020 | -$0.66 | -$0.59 | -$0.76 - -$0.49 | -11.86% | Miss | N/A | 4 | N/A | Nov 5, 2020 | N/A |
| Jun 30, 2020 | -$0.65 | -$0.58 | -$0.76 - -$0.50 | -12.07% | Miss | N/A | 5 | N/A | Jul 30, 2020 | N/A |
| Mar 31, 2020 | -$0.48 | -$0.62 | -$0.74 - -$0.58 | +22.58% | Beat | N/A | 5 | N/A | Apr 28, 2020 | N/A |
| Dec 31, 2019 | -$0.58 | -$0.62 | -$0.72 - -$0.54 | +6.45% | Beat | N/A | 4 | N/A | Feb 26, 2020 | N/A |
| Sep 30, 2019 | -$0.49 | -$0.70 | -$0.75 - -$0.66 | +30.00% | Beat | N/A | 4 | N/A | Oct 28, 2019 | N/A |
| Jun 30, 2019 | -$0.68 | -$0.76 | -$0.78 - -$0.65 | +10.53% | Beat | N/A | 4 | N/A | Aug 12, 2019 | N/A |
| Mar 31, 2019 | -$0.73 | -$0.79 | -$0.89 - -$0.60 | +7.59% | Beat | N/A | 5 | N/A | May 2, 2019 | N/A |
| Dec 31, 2018 | -$0.88 | -$0.75 | -$0.85 - -$0.62 | -17.33% | Miss | -4500.0% | 4 | N/A | Mar 7, 2019 | N/A |
| Sep 30, 2018 | -$0.51 | -$0.53 | -$0.66 - -$0.45 | +3.77% | Beat | N/A | 4 | N/A | Nov 1, 2018 | N/A |
| Jun 30, 2018 | -$0.47 | -$0.50 | -$0.59 - -$0.23 | +6.00% | Beat | N/A | 4 | N/A | Aug 6, 2018 | N/A |
| Mar 31, 2018 | -$0.10 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 24, 2018 | N/A |
| Dec 31, 2017 | $0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2018 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.74, a profit after a loss of $0.61 per share the year before. It was $0.02 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.74 | N/A |
| Dec 31, 2024 | -$0.61 | -438.9% |
| Dec 31, 2023 | $0.18 | -93.1% |
| Dec 31, 2022 | $2.59 | N/A |
| Dec 31, 2021 | -$2.30 | N/A |
| Dec 31, 2020 | -$2.58 | N/A |
| Dec 31, 2019 | -$2.48 | N/A |
| Dec 31, 2018 | -$1.96 | -9900.0% |
| Dec 31, 2017 | $0.02 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,500 words across 11 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,482 | 11 | |
| 2026Q2 | Jun 30, 2026 | 4,959 | 12 | |
| 2026Q1 | Mar 31, 2026 | 4,580 | 14 | |
| 2025Q4 | Dec 31, 2025 | 3,883 | 11 | |
| 2025Q3 | Sep 30, 2025 | 5,152 | 13 | |
| 2025Q2 | Jun 30, 2025 | 4,547 | 12 | |
| 2025Q1 | Mar 31, 2025 | 4,362 | 12 | |
| 2024Q4 | Dec 31, 2024 | 3,171 | 9 |
2026Q3 Earnings Call
Opening remarks
Jonathan Kirshenbaum Investor Relations Thank you, operator. Good morning, everyone, and welcome to the Kiniksa Pharmaceuticals Third Quarter 2026 Earnings Call. A press release highlighting our financial results and recent portfolio execution can be found on our website under the Investors section. As for the agenda, our Chief Executive Officer, Sanj K. Patel, will start with an introduction. From there, Ross Moat, our Chief Operating Officer, will provide an update on ARCALYST commercial execution. After that, Mark Ragosa, our Chief Financial Officer, will review our third quarter 2026 financial results. Finally, Sanj will return at the end of the call to share closing remarks and kick off the Q&A session, for which John Paolini, Kiniksa's Chief Medical Officer, will also be on the line. Before getting started, please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from such statements. A review of these statements and risk factors can be found on this slide, as well as under the caption Risk Factors contained in our SEC filings. These statements speak only as of the date of this presentation, and we undertake no obligation to update such statements except as required by law. With that, I'll turn it over to Sanj.
Sanj K. Patel CEO Thanks, Jonathan, and good morning or good afternoon, everyone. Over the last 10, 11 years, we've built this company through multiple stages of growth, and today, I'm as excited as ever about what the team and I can accomplish together in the years ahead. Kiniksa continues to build a leading IL-1 alpha and beta inhibition franchise driven by the commercialization of ARCALYST in recurrent pericarditis, as well as our progress with KPL-387 and KPL-1161. This morning, we announced via a press release that we've raised our full-year revenue guidance to between $1.045 billion and $1.050 billion. We continue to see robust growth with ARCALYST in recurrent pericarditis, driven by strong execution and strategic investments across the business. On the clinical side, we're excited about the progress of KPL-387 and KPL-1161. The pivotal phase III study with KPL-387 continues to enroll and dose patients. We announced today that we expect data from this trial in the second half of 2027. The team and I are really looking forward to potentially launching this drug in the 2028, 2029 timeframe. In addition to providing an important treatment option for patients with recurrent pericarditis, we believe KPL-387 could help grow the market by enabling a once-monthly subQ dosing. We are also on track to have KPL-1161, our quarterly IL-1 alpha and beta inhibitor, in a phase I clinical trial by the end of this year.
Frequently Asked Questions About KNSA
When is Kiniksa Pharmaceuticals's next earnings date?
Kiniksa Pharmaceuticals's next earnings report is expected for Feb 22, 2027.
Did KNSA beat earnings estimates last quarter?
Yes. Kiniksa Pharmaceuticals reported EPS of $0.56 for the quarter ended Sep 30, 2026, above the $0.32 estimate, a 75.00% surprise.
What EPS do analysts expect from KNSA next quarter?
The consensus EPS estimate for Kiniksa Pharmaceuticals for the quarter ending Dec 31, 2026 is $0.29 from 9 analysts, with estimates from $0.16 to $0.43.
How often does KNSA beat earnings estimates?
Kiniksa Pharmaceuticals beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -90.48%.
KNSA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts